Cabozantinib + Nivolumab for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing whether cabozantinib alone or with nivolumab is better than other treatments for patients with a type of lung cancer called non-squamous non-small cell lung cancer. Cabozantinib stops cancer cells from growing, while nivolumab helps the immune system fight the cancer. The goal is to see if these treatments can help patients live longer without their cancer getting worse.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must not be on certain medications like strong CYP3A4 inducers or continuous systemic corticosteroids above a certain dose. It's best to discuss your current medications with the trial team to ensure they don't interfere with the study.
Is the combination of Cabozantinib and Nivolumab safe for humans?
How is the drug combination of Cabozantinib and Nivolumab unique for lung cancer treatment?
The combination of Cabozantinib and Nivolumab is unique because it pairs a tyrosine kinase inhibitor (Cabozantinib) with an immune checkpoint inhibitor (Nivolumab), potentially offering a dual approach by targeting cancer cell growth and enhancing the immune system's ability to fight cancer, which is different from traditional chemotherapy options.678910
What data supports the effectiveness of the drug combination of Cabozantinib and Nivolumab for lung cancer?
Nivolumab has been shown to improve survival in patients with advanced squamous cell non-small cell lung cancer (NSCLC) after chemotherapy. Cabozantinib has demonstrated antitumor effects in various cancers and may work well with immune checkpoint inhibitors like Nivolumab, potentially enhancing the immune system's ability to fight cancer.611121314
Who Is on the Research Team?
Joel W Neal
Principal Investigator
ECOG-ACRIN Cancer Research Group
Are You a Good Fit for This Trial?
This trial is for adults with non-squamous non-small cell lung cancer (NSCLC) who've had one round of platinum-based chemo and checkpoint inhibitor immunotherapy. They must have manageable side effects from past treatments, no major organ issues, can swallow pills, and have no severe heart conditions or untreated viral infections. Pregnant individuals or those planning to conceive are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive either cabozantinib alone, cabozantinib with nivolumab, or standard chemotherapy. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Correlative biomarker research
Correlative biomarker research will be performed on tissue and blood specimens collected within this trial.
What Are the Treatments Tested in This Trial?
Interventions
- Cabozantinib S-malate
- Nab-paclitaxel
- Nivolumab
Cabozantinib S-malate is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor